Appetite Suppression Research Peptides

The peptides included in this collection are categorized based on the strength of their evidence for appetite suppression. While some have received regulatory approval and are well-studied, others remain in exploratory stages of research. The mechanisms through which these peptides exert their effects often involve complex interactions with hormonal pathways that regulate appetite and energy balance. Studies suggest that the efficacy of these peptides can vary significantly based on individual metabolic conditions and the specific mechanisms they engage. This overview serves as a foundational understanding for researchers interested in the therapeutic potential of these peptides in addressing obesity and related metabolic disorders.

Semaglutide, marketed under the brand names Ozempic for type 2 diabetes and Wegovy for chronic weight management, is a GLP-1 receptor agonist that has garnered substantial attention due to its efficacy in weight reduction. Research indicates that semaglutide promotes weight loss by mimicking the GLP-1 hormone, which enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, thereby increasing feelings of fullness. The injectable form boasts an impressive bioavailability of approximately 89%, while the oral formulation, Rybelsus, requires specific administration conditions that affect its absorption. Clinical trials have demonstrated significant weight loss outcomes; however, it is important to note that semaglutide is not without risks, as the FDA has issued warnings regarding counterfeit products, underscoring the need for caution in sourcing this peptide.

Tirzepatide stands out as a dual agonist of GIP and GLP-1 receptors, showcasing a unique mechanism that may enhance metabolic outcomes beyond those achieved with GLP-1 alone. This 39-amino-acid peptide, which incorporates a fatty di-acid moiety to facilitate albumin binding, allows for convenient once-weekly dosing. Research indicates that tirzepatide not only improves glucose-dependent insulin secretion and suppresses glucagon but also appears to amplify satiety signaling, leading to significant weight loss. Preliminary trials have reported enhanced serum adiponectin levels, a biomarker associated with improved lipid and glucose metabolism, suggesting potential cardiovascular benefits. Despite its promising profile, further studies are needed to fully elucidate the long-term effects and safety of tirzepatide in diverse populations.

Melanotan II is a synthetic analogue of alpha-MSH, primarily known for its ability to induce skin tanning through non-selective activation of melanocortin receptors. While its initial development aimed at photoprotection, research has revealed additional effects on sexual function and appetite regulation, particularly through the activation of MC4R receptors in the central nervous system. This peptide's non-selective nature means that it simultaneously influences multiple pathways, which can lead to varied physiological effects. However, it is crucial to note that Melanotan II is not approved for human use in any jurisdiction, and regulatory agencies have issued warnings concerning its safety. The lack of clinical validation and potential adverse effects necessitate caution when considering its use in research settings.

Retatrutide represents a novel approach in appetite suppression as a triple receptor agonist targeting GLP-1, GIP, and glucagon pathways. Currently undergoing Phase III trials, including the TRIUMPH series, this peptide has shown promise in significantly reducing body weight while also addressing comorbid conditions such as osteoarthritis. The mechanism of action involves a synergistic effect that combines appetite reduction, improved glucose metabolism, and enhanced energy expenditure, setting it apart from dual agonists like tirzepatide. Early results indicate substantial weight loss, with projections for FDA approval anticipated between 2027 and 2028. However, as with many investigational drugs, the long-term effects and comprehensive safety profile of retatrutide remain to be fully established through ongoing research.

Liraglutide, the first GLP-1 agonist approved for obesity management, is marketed as Saxenda for weight management and Victoza for type 2 diabetes. This peptide enhances glucose-dependent insulin secretion while also suppressing glucagon release and delaying gastric emptying, leading to increased satiety. Its mechanism is supported by a fatty acid side chain that promotes prolonged circulation in the bloodstream, allowing for once-daily dosing. Clinical trials have demonstrated significant weight loss benefits, although individual responses can vary widely. As with other peptides in this category, it is essential to consider the potential side effects and contraindications associated with liraglutide, emphasizing the importance of thorough patient evaluation in clinical applications.

Cagrilintide is a long-acting synthetic analog of human amylin, developed by Novo Nordisk as both a standalone treatment and in combination with semaglutide (CagriSema). This innovative combination aims to engage complementary pathways in appetite regulation, with amylin influencing satiety circuits in the hindbrain and GLP-1 modulating hypothalamic and gut pathways. The significance of this dual approach is underscored by the filing for FDA approval anticipated in 2026. Research indicates that cagrilintide activates amylin receptors, which promote meal-related satiety while also slowing gastric emptying and suppressing glucagon release. Its structural modifications, including a fatty acid side chain, extend its half-life to about one week, facilitating once-weekly administration. While promising, ongoing studies are needed to further elucidate its efficacy and safety profile in diverse populations.

Exenatide, a 39-amino-acid GLP-1 receptor agonist derived from the saliva of the Gila monster, was the first GLP-1 agonist to receive FDA approval for the management of type 2 diabetes. Byetta, its immediate-release formulation, was approved in April 2005, followed by Bydureon, a once-weekly formulation, in January 2012. Exenatide's structural resemblance to human GLP-1, coupled with its resistance to DPP-4 degradation, enhances its therapeutic potential. Mechanistically, exenatide stimulates glucose-dependent insulin secretion, suppresses glucagon levels, and slows gastric emptying, contributing to appetite regulation. Its immediate-release formulation has a half-life of approximately 2.4 hours, while the extended-release formulation utilizes microspheres for sustained release over a week. Despite its established role in diabetes management, further studies are warranted to explore its potential applications in appetite suppression in non-diabetic populations.

Dulaglutide is a GLP-1 receptor agonist characterized by a unique fusion protein design that links a GLP-1 analog to a modified human IgG4 Fc fragment. This design extends its half-life to approximately five days, allowing for once-weekly dosing. Approved by the FDA, dulaglutide operates by enhancing glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying, all of which contribute to appetite regulation. Its amino acid modifications enhance resistance to DPP-4 degradation, increasing its therapeutic efficacy. Studies have shown that dulaglutide effectively reduces body weight in individuals with type 2 diabetes, but its broader implications for appetite suppression in other populations remain an area of active research. The metabolic effects and long-term safety profile of dulaglutide necessitate further exploration in diverse clinical settings.

Lixisenatide, a once-daily GLP-1 receptor agonist, is derived from exendin-4 and features a modified C-terminal tail with six lysine residues, enhancing its stability against DPP-4 degradation. Approved as Lyxumia in various markets, lixisenatide is also available in combination with insulin glargine as Soliqua 100/33. Its mechanism involves activating GLP-1 receptors to stimulate insulin secretion and suppress glucagon, particularly postprandially, which is crucial for appetite regulation. With a half-life of approximately three hours, lixisenatide's short-acting profile allows for effective management of postprandial glucose levels. While studies indicate its efficacy in reducing food intake, further research is needed to understand its role in appetite suppression across different patient demographics, especially in those without diabetes.

Pramlintide, marketed as Symlin, is a synthetic analog of amylin that mimics the physiological actions of the endogenous peptide. With three proline substitutions that prevent amyloid aggregation, pramlintide effectively slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety. Approved by the FDA for use in diabetes management, pramlintide's mechanism involves binding to amylin receptors in the central nervous system, influencing appetite regulation. Its relatively short half-life of approximately 48 minutes necessitates multiple daily doses. While clinical trials have demonstrated its potential in reducing caloric intake and aiding weight management, further studies are required to assess its long-term effects and safety in broader populations beyond those with diabetes.

Setmelanotide, known as Imcivree, is an MC4R agonist specifically developed for the treatment of Bardet-Biedl syndrome (BBS). This cyclic 8-amino-acid peptide restores signaling in the hypothalamic leptin-melanocortin pathway, which is often disrupted in patients with genetic deficiencies affecting this system. By directly activating the MC4R, setmelanotide addresses severe hyperphagia and early-onset obesity associated with conditions such as POMC, PCSK1, or LEPR deficiencies. Its high affinity for MC4R, with an EC50 of approximately 0.27 nM, underscores its potential effectiveness in appetite suppression. Although setmelanotide has received FDA approval, ongoing research is crucial to fully elucidate its therapeutic applications and to explore its effects on appetite regulation in broader contexts.

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly, with a molecular weight of 4,563.06 g/mol. This peptide is administered via a once-weekly injection and is designed to leverage the appetite-suppressing and glucose-lowering properties of GLP-1 alongside the energy-expending effects of glucagon. Notably, the National Medical Products Administration (NMPA) in China approved mazdutide in June 2025 for chronic weight management and in September 2025 for glycemic control in type 2 diabetes, marking it as the first dual GLP-1/glucagon agonist to receive regulatory approval globally. The mechanism of action involves fatty acid acylation, which enhances albumin binding and extends the half-life, allowing for effective once-weekly dosing. Research indicates that the GLP-1 receptor activation leads to increased insulin secretion and reduced appetite, while glucagon receptor activation stimulates hepatic lipid oxidation and energy expenditure, presenting a multifaceted approach to weight management.

Adipotide (FTPP) is an experimental chimeric peptidomimetic with a molecular weight of approximately 3,200 g/mol, designed to target prohibitin—a protein overexpressed in the endothelial cells of white adipose tissue. This peptide consists of a domain that binds to prohibitin (CKGGRAKDC) linked to a proapoptotic domain (D(KLAKLAK)2). While preclinical studies suggested that Adipotide could induce fat loss by disrupting the blood supply to adipose tissue, leading to the ischemic death of adipocytes, clinical development was halted due to reversible kidney toxicity observed in primate studies. The mechanism relies on selective binding to fat tissue vasculature, which is less prevalent in other tissues, but the associated renal toxicity highlights the need for caution in interpreting preclinical efficacy in the context of human safety.

Tesofensine is a triple monoamine reuptake inhibitor that targets serotonin, norepinephrine, and dopamine, initially developed for neurological disorders such as Alzheimer's and Parkinson's disease. The compound, which underwent Phase II–III clinical trials, has shown promise in weight loss applications. Its mechanism involves the inhibition of presynaptic reuptake of these neurotransmitters, leading to increased synaptic concentrations. This elevation in monoamines is associated with appetite suppression through serotonergic pathways, while noradrenergic and dopaminergic mechanisms contribute to enhanced thermogenesis and energy expenditure. Unlike peptides that primarily act via gut hormone signaling, tesofensine's centrally mediated action presents a distinct approach to appetite regulation. However, further studies are needed to fully elucidate its efficacy and safety in weight management contexts.

Cholecystokinin (CCK) is a well-characterized endogenous peptide hormone that plays a crucial role in satiety and digestive processes. Released by I-cells in the duodenum and jejunum in response to fat and protein intake, CCK has been extensively studied for its physiological effects, including meal termination, gallbladder contraction, and stimulation of pancreatic enzyme secretion. CCK operates through CCK-A receptors in the periphery and CCK-B receptors centrally, influencing both satiety signaling and modulation of anxiety and pain perception. The rapid release of CCK postprandially activates vagal afferent neurons, sending signals to the nucleus tractus solitarius in the brainstem to promote feelings of fullness. Despite its well-known physiological functions, therapeutic applications of CCK are limited due to its short half-life of 1-2 minutes, which results from rapid enzymatic degradation. Ongoing research continues to explore the potential of CCK analogs in appetite regulation.